As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The global cancer therapeutics market size is expected to expand in the coming years. The demand for cancer therapeutics is powered by the increased government spending in R&D firms. The rising occurrence of cancer worldwide also increases the growth of the cancer therapeutics industry. Based on the application, breast cancer accounts for the largest market share in 2019 and, due to its high prevalence, the form of cancer is projected to remain dominant over the forecast period. Researchers at the ICR in London have confirmed that they have discovered a way to inhibit the escape of three negative breast cancer cells, and this new approach will interrupt the main mechanism in the progression of cancer. The team used a drug named BOS172722 from Boston Pharmaceuticals to rapidly differentiate cancer cells. Such developments are expected to drive the growth of the segment. In addition, breast cancer is also identified as the most prevalent cancer in the United States, which supports the segment's rise in the cancer therapeutics industry.
In March 2020, AbbVie (NYSE: ABBV), one of the key players in the industry, received a much-awaited approval for VENCLYXTO combination regime by the European Commission for patients with previously untreated chronic lymphocytic leukaemia. It is the third approval of VENCLYXTO, the first-ever B-cell lymphoma-2 (BCL-2) inhibitor. BCL-2 refers to a protein that prohibits apoptosis from occurring in cancer cells, a mechanism leading to the eventual death or self-destruction of cancer cells. VENCLYXTO is also approved for use in combination with rituximab for adult patients with CLL who have undergone at least one prior therapy and as in case of 17p deletion or TP53 mutation in adult patients who were not eligible for or failed a B- pathway inhibitor as a monotherapy in the treatment of CLL (chronic lymphocytic leukaemia).
Market Analysis by Top Selling Drugs, Application, and Regions:
Key Findings of the Report:
Key Offerings of the Report:
The major key players in the global cancer therapeutics market include companies like AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others. The comprehensive report covers their market share, capacity, and latest developments like mergers and acquisitions and capacity expansions.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.